7k80
From Proteopedia
KIR3DL1*001 in complex with HLA-A*24:02 presenting the RYPLTFGW peptide
Structural highlights
Publication Abstract from PubMedHLA class I molecules that represent ligands for the inhibitory killer cell Ig-like receptor (KIR) 3DL1 found on NK cells are categorically defined as those HLA-A and HLA-B allotypes containing the Bw4 motif, yet KIR3DL1 demonstrates hierarchical recognition of these HLA-Bw4 ligands. To better understand the molecular basis underpinning differential KIR3DL1 recognition, the HLA-A(Bw4) family of allotypes were investigated. Transfected human 721.221 cells expressing HLA-A*32:01 strongly inhibited primary human KIR3DL1(+) NK cells, whereas HLA-A*24:02 and HLA-A*23:01 displayed intermediate potency and HLA-A*25:01 failed to inhibit activation of KIR3DL1(+) NK cells. Structural studies demonstrated that recognition of HLA-A*24:02 by KIR3DL1 used identical contacts as the potent HLA-B*57:01 ligand. Namely, the D1-D2 domains of KIR3DL1 were placed over the alpha1 helix and alpha2 helix of the HLA-A*24:02 binding cleft, respectively, whereas the D0 domain contacted the side of the HLA-A*24:02 molecule. Nevertheless, functional analyses showed KIR3DL1 recognition of HLA-A*24:02 was more sensitive to substitutions within the alpha2 helix of HLA-A*24:02, including residues Ile(142) and Lys(144) Furthermore, the presence of Thr(149) in the alpha2 helix of HLA-A*25:01 abrogated KIR3DL1(+) NK inhibition. Together, these data demonstrate a role for the HLA class I alpha2 helix in determining the hierarchy of KIR3DL1 ligands. Thus, recognition of HLA class I is dependent on a complex interplay between the peptide repertoire, polymorphisms within and proximal to the Bw4 motif, and the alpha2 helix. Collectively, the data furthers our understanding of KIR3DL1 ligands and will inform genetic association and immunogenetics studies examining the role of KIR3DL1 in disease settings. The Role of the HLA Class I alpha2 Helix in Determining Ligand Hierarchy for the Killer Cell Ig-like Receptor 3DL1.,Saunders PM, MacLachlan BJ, Widjaja J, Wong SC, Oates CVL, Rossjohn J, Vivian JP, Brooks AG J Immunol. 2021 Feb 15;206(4):849-860. doi: 10.4049/jimmunol.2001109. Epub 2021 , Jan 13. PMID:33441440[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|